PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
Study Details
Study Description
Brief Summary
This was a phase Ib study of PDR001 in combination with bevacizumab and mFOLFOX6 as first line therapy in patients with metastatic microsatellite stable (MSS) colorectal cancer. The study was to have assessed primarily, the safety and tolerability and then the efficacy of PDR001 in combination with bevacizumab and mFOLFOX6. Particular attention would have been paid to the level of activity of study drug combinations in CMS4 patients (retrospective analysis).
The study was terminated early due to company decision.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 1 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: PDR001
|
Drug: PDR001
400 mg every 4 weeks
Drug: bevacizumab
5 mg/kg every 2 weeks
Drug: mFOLFOX6
Combination of chemotherapy administered every 2 weeks: oxaliplatin (85mg/m2), 5-Fluorouracil (2400mg/m2) and folinic acid (=leucovorin, 400mg/m2)
|
Outcome Measures
Primary Outcome Measures
- Incidence of Dose-limiting toxicity (DLT) [12 months]
- Overall Response Rate (ORR) per investigator assessment using RECIST v1.1 [19 months]
RECIST v1.1 = Response Evaluation Criteria in Solid Tumors v1.1
Secondary Outcome Measures
- Overall response rate (ORR) per central assessment using RECIST v1.1 [Baseline, every 8 weeks until progression per central assessment up to 1 year after last patient last visit]
- Overall survival (OS) [Every 3 months after last visit up to 1 year after last patient last visit]
- Progression free survival [Baseline, every 8 weeks until progression per central assessment up to 1 year after last patient last visit]
- Duration of response (DOR) [Baseline, every 8 weeks until progression per central assessment up to 1 year after last patient last visit]
- Disease control rate (DCR) [Baseline, every 8 weeks until progression per central assessment up to 1 year after last patient last visit]
- Time to response (TTR) [Baseline, every 8 weeks until progression per central assessment up to 1 year after last patient last visit]
- Ctrough [Through end of treatment completion, an average of 14 months]
- Cmax [Through end of treatment completion, an average of 14 months]
- Area under the curve (AUC) [Through end of treatment completion, an average of 14 months]
- Antidrug antibodies (ADA) [Through end of treatment completion, an average of 14 months]
Eligibility Criteria
Criteria
Key inclusion criteria:
-
Patients with metastatic MSS colorectal adenocarcinoma.Note: MSI status will be performed locally by an immunohistochemistry (IHC) or PCR based test for eligibility.
-
Patients must provide a newly obtained or an archival tumor sample corresponding to CRC diagnosis (primary tumor) with sufficient tissue quality (qualified) for analysis (mandatory)
-
Patients must provide a newly obtained tumor tissue sample from a metastatic site (mandatory)
-
Patients who are naïve to systemic treatment in metastatic setting. Patients with previous neoadjuvant or adjuvant chemotherapy (that may have included oxaliplatin or investigational VEGF inhibitors) are eligible if the treatment was completed > 12 months before inclusion.
-
Patients with the presence of at least one lesion with measurable disease as per RECIST 1.1 guidelines. Lesions in previously irradiated areas should not be considered measurable unless they have clearly progressed since the radiotherapy.
-
Patients have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Key exclusion criteria:
-
Patients with MSI-H colorectal adenocarcinoma as defined per local assessment using standard of care testing
-
Patients with metastatic disease amenable to be resected with potentially curative surgery
-
Patients who have received any systemic treatment for metastatic disease.
-
Patients with a history of prior treatment with anti-PD-1, anti-PD-L1, anti-PDL2, anti-CTLA-4 antibodies, other checkpoint inhibitors
-
Patients who had received radiation within 14 days prior to the first dose of study drug
Other protocol-defined inclusion/exclusion criteria may apply
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Novartis Investigative Site | Sutton | Surrey | United Kingdom | SM2 5PT |
Sponsors and Collaborators
- Novartis Pharmaceuticals
Investigators
- Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- CPDR001I2101
- 2017-000520-96